会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
    • Interalpha胰蛋白酶抑制剂生物聚合物标志物表明胰岛素抵抗
    • US07329501B2
    • 2008-02-12
    • US11439587
    • 2006-05-23
    • George JackowskiJohn Marshall
    • George JackowskiJohn Marshall
    • G01N33/53
    • C07K14/8114Y10T436/24
    • The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
    • 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在的能力,以相对于识别所述生物聚合物的存在和/或不存在,预测疾病风险评估以及开发针对所述疾病的治疗途径。
    • 7. 发明授权
    • Protein biopolymer markers indicative of alzheimer's disease
    • 指示阿尔茨海默病的蛋白质生物聚合物标记物
    • US07074576B2
    • 2006-07-11
    • US09992672
    • 2001-11-23
    • George JackowskiJohn Marshall
    • George JackowskiJohn Marshall
    • G01N33/567A61K38/00
    • G01N33/6848C07K7/08G01N33/6851Y10S436/811
    • The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
    • 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征与识别生物聚合物的存在和/或不存在相关的至少一种疾病状态的存在或不存在的能力,预测疾病风险评估以及开发针对该疾病的治疗途径。